Bulk Manufacturer of Controlled Substances Application: Noramco, Inc., 31227 [2020-11077]

Download as PDF Federal Register / Vol. 85, No. 100 / Friday, May 22, 2020 / Notices samer.musallam@usdoj.gov, Email: lowell.stern@usdoj.gov. Attorneys for Plaintiff United States Active Pharmaceutical Ingredient (API) for supply to its customers. In reference to drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetics. No other activities for these drug codes are authorized for this registration. This notice does not constitute an evaluation or determination of the merits of the company’s application. [FR Doc. 2020–11073 Filed 5–21–20; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–645] Bulk Manufacturer of Controlled Substances Application: Noramco, Inc. ACTION: Notice of application. William T. McDermott, Assistant Administrator. [FR Doc. 2020–11077 Filed 5–21–20; 8:45 am] BILLING CODE 4410–09–P Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 21, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: In accordance with 21 CFR 1301.33(a), this is notice that on February 26, 2020, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801– 4417, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances: SUPPLEMENTARY INFORMATION: Controlled substance Marihuana ...................... Tetrahydrocannabinols .. Codeine-N-oxide ............ Dihydromorphine ........... Hydromorphinol ............. Morphine-N-oxide .......... Amphetamine ................ Lisdexamfetamine ......... Methylphenidate ............ Nabilone ........................ Phenylacetone ............... Codeine ......................... Dihydrocodeine .............. Oxycodone .................... Hydromorphone ............. Hydrocodone ................. Morphine ........................ Oripavine ....................... Thebaine ........................ Opium extracts .............. Opium fluid extract ........ Opium tincture ............... Opium, powdered .......... Opium, granulated ......... Oxymorphone ................ Noroxymorphone ........... Tapentadol ..................... Drug code 7360 7370 9053 9145 9301 9307 1100 1205 1724 7379 8501 9050 9120 9143 9150 9193 9300 9330 9333 9610 9620 9630 9639 9640 9652 9668 9780 Schedule I I I I I I II II II II II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances as an VerDate Sep<11>2014 18:07 May 21, 2020 Jkt 250001 DEPARTMENT OF JUSTICE National Institute of Corrections Advisory Board; Notice of Meeting This notice announces a forthcoming virtual meeting of the National Institute of Corrections (NIC) Advisory Board. The meeting will be open to the public. Name of the Committee: NIC Advisory Board. General Function of the Committee: To aid the National Institute of Corrections in developing long-range plans, advise on program development, and recommend guidance to assist NIC’s efforts in the areas of training, technical assistance, information services, and policy/program development assistance to Federal, state, and local corrections agencies. Date and Time: 11:00 a.m.–1:30 p.m. on Friday, June 19, 2020 (approximate). Location: Virtual Platform. Contact Person: Susan Walters, Executive Assistant, National Institute of Corrections, 320 First Street NW, Room 901–3, Washington, DC 20534. To contact Ms. Walters, please call (202) 353–4213. Agenda: On Friday, June 19, 2020, the Advisory Board will receive a brief Agency Report from the NIC Acting Director, with time for questions and planning for subsequent FY20–FY21 Advisory Board meeting(s). Procedure: On June 19, 2020, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before June 8, 2020. Oral presentations from the public will be scheduled between approximately 1:00 p.m. to 1:15 p.m. on June 19, 2020. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the PO 00000 Frm 00093 Fmt 4703 Sfmt 4703 31227 evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before June 8, 2020. General Information: NIC welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Susan Walters at least 7 days in advance of the meeting. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Shaina Vanek, Acting Director, National Institute of Corrections. [FR Doc. 2020–11051 Filed 5–21–20; 8:45 am] BILLING CODE 4410–36–P DEPARTMENT OF LABOR Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; Notice to Employees of Coverage Options Under Fair Labor Standards Act Section 18B Notice of availability; request for comments. ACTION: The Department of Labor (DOL) is submitting this Employee Benefits Security Administration (EBSA)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited. DATES: The OMB will consider all written comments that agency receives on or before June 22, 2020. ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Comments are invited on: (1) Whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; (2) if the information will be processed and used SUMMARY: E:\FR\FM\22MYN1.SGM 22MYN1

Agencies

[Federal Register Volume 85, Number 100 (Friday, May 22, 2020)]
[Notices]
[Page 31227]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-11077]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-645]


Bulk Manufacturer of Controlled Substances Application: Noramco, 
Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before July 21, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on February 26, 2020, Noramco, Inc., 500 Swedes Landing 
Road, Wilmington, Delaware 19801-4417, applied to be registered as a 
bulk manufacturer of the following basic class(es) of controlled 
substances:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Marihuana..............................     7360  I
Tetrahydrocannabinols..................     7370  I
Codeine-N-oxide........................     9053  I
Dihydromorphine........................     9145  I
Hydromorphinol.........................     9301  I
Morphine-N-oxide.......................     9307  I
Amphetamine............................     1100  II
Lisdexamfetamine.......................     1205  II
Methylphenidate........................     1724  II
Nabilone...............................     7379  II
Phenylacetone..........................     8501  II
Codeine................................     9050  II
Dihydrocodeine.........................     9120  II
Oxycodone..............................     9143  II
Hydromorphone..........................     9150  II
Hydrocodone............................     9193  II
Morphine...............................     9300  II
Oripavine..............................     9330  II
Thebaine...............................     9333  II
Opium extracts.........................     9610  II
Opium fluid extract....................     9620  II
Opium tincture.........................     9630  II
Opium, powdered........................     9639  II
Opium, granulated......................     9640  II
Oxymorphone............................     9652  II
Noroxymorphone.........................     9668  II
Tapentadol.............................     9780  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as an Active Pharmaceutical Ingredient (API) for supply to its 
customers. In reference to drug codes 7360 (Marihuana) and 7370 
(Tetrahydrocannabinols), the company plans to bulk manufacture these 
drugs as synthetics. No other activities for these drug codes are 
authorized for this registration. This notice does not constitute an 
evaluation or determination of the merits of the company's application.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-11077 Filed 5-21-20; 8:45 am]
 BILLING CODE 4410-09-P